Whilst the low level of detection of BRCA1 and BRCA2 mutations amongst individuals with HER2+ breast cancers is clearly important in assessing carrier likelihood, the presence of a triple negative breast cancer clearly increases the likelihood of identifying a BRCA1/2 mutation. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.